K4 Elite logo K4 Elite
Home / Peptide Library / Thymosin Alpha-1
Well Researched

Thymosin Alpha-1

Inflammation & Immunity · ['Thymalfasin', 'Tα1', 'TA1', 'Zadaxin']

A 28-amino-acid thymic peptide studied for its immunomodulatory effects on T-cell maturation and innate immune signaling.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C129H215N33O55
Molecular Weight
3108.3 g/mol
PubChem
CID 16130571 ↗
Research Level
Well Researched
Browse the store →
Thymosin Alpha-1 chemical structure

Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid acetylated peptide originally isolated from thymosin fraction 5 of the thymus gland. It is one of the most extensively characterized thymic peptides and has been the subject of research into immune regulation across infectious, oncologic, and inflammatory contexts.

The peptide is approved or registered as a pharmaceutical (thymalfasin) in a number of countries for uses such as adjuvant hepatitis therapy and immune support, though regulatory status varies by jurisdiction. In laboratory settings it is studied as a modulator that appears to shift immune responses rather than broadly stimulate or suppress them.

Research interest centers on its interactions with pattern-recognition receptor signaling and on its influence over the maturation and differentiation of immune cell populations.

Investigations indicate that Thymosin Alpha-1 acts in part through Toll-like receptor pathways, with reported signaling via TLR2 and TLR9 in dendritic cells and monocytes, influencing downstream activation of transcription factors and cytokine production. This is thought to promote maturation of dendritic cells and support differentiation of T-lymphocyte subsets.

Additional studies describe effects on the balance of pro- and anti-inflammatory cytokines and on natural killer cell activity, suggesting a context-dependent, immunorestorative profile rather than a single defined receptor mechanism.

  • Modulation of T-cell maturation and dendritic cell function via Toll-like receptor signaling [1]
  • Adjuvant investigation alongside antiviral regimens in chronic hepatitis B and C models and trials [2]
  • Exploration in sepsis and critical-illness immune dysregulation [3]
  • Studies of natural killer cell activity and antitumor immune surveillance [4]
  • Assessment as an adjuvant to vaccination responses in immunocompromised or aged populations [1]
  • Investigation in acute respiratory infection and inflammatory contexts [3]
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Sepsis immune modulation (human trial) [3]: A randomized controlled trial in patients with severe sepsis evaluated thymosin alpha-1 administration and measured changes in mHLA-DR expression and 28-day mortality; investigators reported improvements in monitored immune markers in the treatment group.

Chronic hepatitis B adjuvant studies (human) [2]: Controlled trials combining thymalfasin with antiviral therapy assessed virologic and biochemical response endpoints such as HBV DNA and ALT normalization, reporting differences in sustained response measures relative to comparator arms.

Dendritic cell signaling (in vitro) [1]: Cell-culture work exposed human dendritic cells and monocytes to the peptide and measured TLR-dependent maturation markers and cytokine output, characterizing the receptor pathways engaged.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Interferon-alphaSynergistic
Studied together in antiviral hepatitis research where combined immune and antiviral effects were assessed.
Vaccine antigensSynergistic
Investigated as an adjuvant to enhance measured antibody responses in research settings.
Immunosuppressive agentsCaution
Opposing immunomodulatory directions make combined effects a theoretical research consideration.
Standard antiviral therapyCompatible
Frequently co-administered in study designs without reported pharmacologic conflict.
  1. Romani et al., Thymosin alpha1 and TLR signaling (Ann N Y Acad Sci)
  2. Thymalfasin in chronic hepatitis B (meta-analysis)
  3. Wu et al., Thymosin alpha1 in severe sepsis (ETASS trial, Crit Care)
  4. Garaci et al., Thymosin alpha1 in cancer and immunity (Ann N Y Acad Sci)
  5. PubChem CID 16130571 (Thymalfasin)
What is Thymosin Alpha-1?
It is a 28-amino-acid thymic peptide studied for its role in modulating immune cell maturation and signaling.
How is it thought to work?
Research suggests it engages Toll-like receptor pathways and influences dendritic cell and T-cell differentiation, producing a context-dependent immunomodulatory effect.
What research areas involve this peptide?
Published work spans antiviral hepatitis adjuvant studies, sepsis immune dysregulation, vaccine response, and natural killer cell activity.
Is it an approved drug?
A pharmaceutical form (thymalfasin) is registered in some countries for specific indications, but regulatory status varies and this material is provided for research use only.
Can this be used to treat or prevent disease?
No. This entry is a research reference only. The material is not offered for human or veterinary diagnosis, treatment, or prevention of any condition.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.